| Literature DB >> 31806944 |
Karolina Walewicz1, Jakub Taradaj2,3, Katarzyna Rajfur1, Kuba Ptaszkowski4, Michał Tomasz Kuszewski2, Mirosław Sopel5, Robert Dymarek5.
Abstract
PURPOSE: This prospective, randomized and single-blinded study assesses the influence of radial extracorporeal shock wave therapy (rESWT) in patients with low back pain (LBP).Entities:
Keywords: ESWT; functional state; low back pain; physical therapy; shock waves
Mesh:
Year: 2019 PMID: 31806944 PMCID: PMC6857735 DOI: 10.2147/CIA.S224001
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Quality Of Clinical Studies On rESWT And LBP
| Authors | PEDro Scale* [Points] | Limitations |
|---|---|---|
| Tomska et al | 3/10 | No blind subject; no blind therapist; no blind assessors; no adequate follow-up; no intention-to-treat analysis; no point estimates and variability |
| Lin et al | 6/10 | No baseline comparability; no blind therapist; no blind assessors; no adequate follow-up |
| Han et al | 3/10 | No blind subject; no blind therapist; no blind assessors; no adequate follow-up; no intention-to-treat analysis; no point estimates and variability |
| Lee et al | 3/10 | No blind subject; no blind therapist; no blind assessors; no adequate follow-up; no intention-to-treat analysis; no point estimates and variability |
Note: *According to Physiotherapy Evidence Database methodology
Demographic Characteristics Of Participants In The Study
| Item | Group | P-value | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | x̅ | Me | Min | Max | Q1 | Q3 | SD | |||
| Age [years] | A | 20 | 51.1 | 53.0 | 36.0 | 71.0 | 44.5 | 55.5 | 8.4 | 0.105* |
| B | 20 | 55.8 | 55.0 | 38.0 | 74.0 | 49.5 | 59.5 | 9.3 | ||
| Height [cm] | A | 20 | 165.7 | 165.5 | 150.0 | 180.0 | 162.5 | 170.0 | 7.8 | 0.465* |
| B | 20 | 165.0 | 164.0 | 152.0 | 180.0 | 159.0 | 169.0 | 7.7 | ||
| Body weight [kg] | A | 20 | 77.2 | 73.0 | 55.0 | 121.0 | 65.0 | 85.0 | 17.3 | 0.394* |
| B | 20 | 80.4 | 81.0 | 55.0 | 102.0 | 67.5 | 96.5 | 15.2 | ||
| Duration of disease [years] | A | 20 | 9.8 | 8.0 | 3.0 | 20.0 | 5.0 | 14.0 | 5.1 | 0.725* |
| B | 20 | 9.0 | 8.5 | 3.0 | 17.0 | 5.0 | 12.0 | 4.1 | ||
| Modic class [°] | A | 20 | 3.1 | 3.0 | 3.0 | 4.0 | 3.0 | 3.0 | 0.2 | 0.797* |
| B | 20 | 3.1 | 3.0 | 3.0 | 4.0 | 3.0 | 3.0 | 0.3 | ||
| Sex [n/%] | A | Women n=14 (70%) | 0.723** | |||||||
| B | Women n=15 (75%) | |||||||||
Note: *U Mann–Whitney test; **Chi2 test.
Abbreviations: n, number of patients; x̅, average; Me, median; Min, minimum value; Max, maximum value; Q1, lower quartile; Q3, upper quartile; SD, standard deviation.
Figure 1The CONSORT flow chart diagram.
Figure 2The rESWT device used in the study.
Figure 3The rESWT procedure in LPB.
The VAS Scale Results In Both Groups A And B [points]
| n | x̅ | Me | Min | Max | Q1 | Q3 | SD | P-value (Main Effect)* | P-value (Multiple Comparisons)** | |
|---|---|---|---|---|---|---|---|---|---|---|
| Before | 20 | 4.7 | 5.0 | 1.0 | 7.0 | 4.0 | 6.0 | 1.9 | Before: After p=0.957 | |
| After | 20 | 4.4 | 4.0 | 1.0 | 8.0 | 3.0 | 6.0 | 1.8 | ||
| 1 month follow-up | 20 | 2.7 | 3.0 | 0.0 | 5.0 | 1.0 | 4.0 | 1.7 | ||
| 3 month follow-up | 20 | 2.0 | 1.0 | 0.0 | 5.0 | 0.0 | 3.5 | 2.0 | ||
| Before | 20 | 4.7 | 5.0 | 1.0 | 7.0 | 4.0 | 5.5 | 1.4 | Before: After | |
| After | 20 | 3.1 | 3.0 | 0.0 | 5.0 | 2.0 | 4.0 | 1.4 | ||
| 1 month follow-up | 19 | 3.5 | 4.0 | 1.0 | 5.0 | 3.0 | 4.0 | 1.1 | ||
| 3 month follow-up | 17 | 4.4 | 4.0 | 2.0 | 6.0 | 4.0 | 5.0 | 1.2 | ||
Notes: P-values with statistical significance are presented in bold. *Friedman test; **Dunn test.
Abbreviations: n, number of patients; x̅, average; Me, median; Min, minimum value; Max, maximum value; Q1, lower quartile; Q3, upper quartile; SD, standard deviation.
The LPS Results In Both Groups A And B [points]
| n | x̅ | Me | Min | Max | Q1 | Q3 | SD | P-value (Main Effect)* | P-value (Multiple Comparisons)** | |
|---|---|---|---|---|---|---|---|---|---|---|
| Before | 20 | 6.3 | 6.0 | 4.0 | 10.0 | 4.0 | 8.0 | 2.0 | Before: After p=0.794 | |
| After | 20 | 5.7 | 6.0 | 2.0 | 10.0 | 4.0 | 7.0 | 2.4 | ||
| 1 month follow-up | 20 | 3.9 | 4.0 | 0.0 | 8.0 | 3.0 | 4.0 | 1.8 | ||
| 3 month follow-up | 20 | 2.2 | 2.0 | 0.0 | 7.0 | 0.0 | 4.0 | 2.0 | ||
| Before | 20 | 6.2 | 5.0 | 2.0 | 11.0 | 4.0 | 8,0.5 | 2.8 | Before: After p=0.078 | |
| After | 20 | 4.3 | 4.0 | 0.0 | 8.0 | 3.0 | 6.0 | 2.1 | ||
| 1 month follow-up | 19 | 5.2 | 5.0 | 0.0 | 9.0 | 4.0 | 7.0 | 2.2 | ||
| 3 month follow-up | 17 | 6.4 | 6.0 | 3.0 | 12.0 | 4.0 | 8.0 | 2.6 | ||
Notes: P-values with statistical significance are presented in bold. *Friedman test; **Dunn test.
Abbreviations: n, number of patients; x̅, average; Me, median; Min, minimum value; Max, maximum value; Q1, lower quartile; Q3, upper quartile; SD, standard deviation.
The ODI Results In Both Groups A And B [points]
| n | x̅ | Me | Min | Max | Q1 | Q3 | SD | P-value (Main Effect)* | P-value (Multiple Comparisons)** | |
|---|---|---|---|---|---|---|---|---|---|---|
| Before | 20 | 16.1 | 16.0 | 10.0 | 25.0 | 11.5 | 21.0 | 5.2 | Before: After p=0.662 | |
| After | 20 | 13.6 | 14.0 | 5.0 | 25.0 | 8.5 | 17.0 | 5.6 | ||
| 1 month follow-up | 20 | 9.3 | 9.5 | 1.0 | 20.0 | 2.0 | 16.0 | 7.1 | ||
| 3 month follow-up | 20 | 9.3 | 8.5 | 0.0 | 31.0 | 1.0 | 15.5 | 8.7 | ||
| Before | 20 | 16.1 | 15.5 | 1.0 | 36.0 | 11.0 | 20.5 | 8.0 | Before: After p=0.405 | |
| After | 20 | 12.3 | 13.0 | 0.0 | 32.0 | 5.5 | 15.0 | 8.4 | ||
| 1 month follow-up | 19 | 14.6 | 14.0 | 2.0 | 31.0 | 10.0 | 20.0 | 7.3 | ||
| 3 month follow-up | 17 | 17.8 | 18.0 | 8.0 | 31.0 | 12.0 | 20.0 | 7.2 | ||
Notes: P-values with statistical significance are presented in bold. *Friedman test; **Dunn test.
Abbreviations: n, number of patients; x̅, average; Me, median; Min, minimum value; Max, maximum value; Q1, lower quartile; Q3, upper quartile; SD, standard deviation.